RNA preparation
Total RNA was isolated and purified from frozen tissue samples using RNeasy Lipid Tissue Mini Kit and RNase-Free DNase Set (Qiagen, Chatsworth, CA) according to manufacturer's protocols. The quality of total RNA was strictly controlled by several parameters. The RNA extracts were first analyzed by Nanodrop 2000 (Thermo Fisher Scientific, Waltham, MA) and gel electrophoresis. RNA quality was determined by the A260/A280 ratio (close to 2), A260/A230 (close to 2), and the presence of two distinct ribosomal bands on gel electrophoresis. Qualified RNAs were further tested using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), and samples with 28S/18S RNA ratio N1 were selected for gene expression profiling [3] . Thirtytwo samples were finally tested, among which two samples C501 (Luminal A) and N513 (normal) were from the same patient, others are unmatched samples.
RNA labeling and hybridization
Cyanine-3 (Cy3) labeled cRNA was prepared from 100 ng RNA using the One-Color Low Input Quick Amp labeling kit (Agilent, Valencia, CA) according to manufacturer's instructions, followed by RNeasy Mini Kit (Qiagen, Valencia, CA) purification. Dye incorporation and cRNA yield were checked with the NanoDrop Spectrophotometer (NanoDrop Technologies, Inc.). Genes with absolute fold change ≥2 and p-value ≤ 0.05 are indicated in red. Plots are generated using GeneSpring 12.6 with moderated t-test and Benjamini-Hochberg testing correction. 
RNA hybridization
For hybridization, 0.6 μg of Cy3-labeled cRNA [4] (specific activity N 8 pmol Cy3/μg cRNA) was fragmented at 60°C for 30 min in a reaction volume of 25 μL containing 1× Agilent fragmentation buffer and 2× Agilent blocking agent following manufacturers' instructions. On completion of the fragmentation reaction, 25 μL of 2× Agilent hybridization buffer was added to the fragmentation mixture and hybridized to Agilent Whole Human Genome Oligo Microarrays (GPL17077) for 17 h at 65°C in a rotating Agilent hybridization oven.
Microarray scanning
After hybridization, microarrays were washed for 1 min at room temperature with GE Wash Buffer 1 (Agilent) and 1 min with 37°C GE Wash buffer 2 (Agilent), then dried using Agilent stabilization and drying solution. Slides were scanned immediately after washing on the Agilent DNA Microarray Scanner (G2505C) using one color scan setting for 1 × 60k array slides (Scan Area 61 × 21 mm, Scan resolution 3 μM, Dye channel is set to Green and Green PMT is set to 100%) [5] .
Data normalization and quality control
The raw signals were log transformed and normalized using the Percentile shift normalization method, the value was set at 75th percentile (Agilent GeneSpring 12.6 manual, 22.2.1, P584) [6] . For each probe, the median of the log summarized values from all the samples was calculated and subtracted from each of the samples to get transformed baseline. The parameter values for experimental grouping were set as Luminal A, Luminal B, Triple negative, and Normal.
Probes with normalized intensity values below 20th percentile were filtered out using the "Filter probe sets by Expression" option. This resulted in 42,875 genes, which were further filtered to exclude probes with standard deviation b 1 in all groups, resulting in 16,822 genes.
Differential expression
Volcano plots, representing the distribution of the fold changes and p-values (obtained from moderated t-test [7] ) of the above 16,822 genes, were shown in Fig. 1 corresponding to each subgroup (Luminal A, Luminal B, and Triple negative). The moderated t-test is one of the statistical tests provided by the GeneSpring 12.6 software as a modification of the unpaired t-test (Agilent GeneSpring 12.6 manual, 22.3.7, P589).
Furthermore, 779 genes were identified with p-value ≤ 0.05 (OneWay ANOVA with asymptotic computation and Benjamin-Hochberg multiple testing corrections) and fold change ≥2 [8, 9] in all three breast cancer subtypes. The heat map for these 779 genes is shown in Fig. 2 .
Conclusion
Herein we described the gene regulation information for breast cancer gene profiling using Agilent SurePrint G3 Human Gene Expression Microarray technology. Our gene expression microarray data provided an important resource for exploring and identifying gene biomarkers involved in breast cancer.
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